Your browser is no longer supported. Please, upgrade your browser.
Settings
CASI CASI Pharmaceuticals, Inc. daily Stock Chart
CASI [NASD]
CASI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own49.87% Shs Outstand92.81M Perf Week-12.82%
Market Cap284.00M Forward P/E- EPS next Y-0.19 Insider Trans0.00% Shs Float42.70M Perf Month-46.22%
Income-16.10M PEG- EPS next Q- Inst Own21.30% Short Float8.14% Perf Quarter-58.14%
Sales- P/S- EPS this Y-3.50% Inst Trans0.19% Short Ratio11.83 Perf Half Y-56.29%
Book/sh0.97 P/B3.15 EPS next Y- ROA-28.40% Target Price7.00 Perf Year30.21%
Cash/sh0.73 P/C4.21 EPS next 5Y- ROE-31.40% 52W Range1.94 - 8.89 Perf YTD-5.85%
Dividend- P/FCF- EPS past 5Y25.80% ROI- 52W High-66.65% Beta1.32
Dividend %- Quick Ratio26.00 Sales past 5Y- Gross Margin- 52W Low52.85% ATR0.33
Employees20 Current Ratio26.00 Sales Q/Q- Oper. Margin- RSI (14)13.97 Volatility8.14% 7.96%
OptionableNo Debt/Eq0.00 EPS Q/Q-70.20% Profit Margin- Rel Volume2.88 Prev Close3.06
ShortableYes LT Debt/Eq0.02 EarningsNov 13 BMO Payout- Avg Volume293.67K Price2.97
Recom2.00 SMA20-27.74% SMA50-48.96% SMA200-48.20% Volume69,005 Change-3.09%
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
Oct-18-18 08:40AM  Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-02-18 07:00AM  CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization PR Newswire
Sep-28-18 07:00AM  CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer PR Newswire -9.50%
Sep-14-18 07:00AM  CASI Pharmaceuticals Announces $48.5 Million Private Placement PR Newswire
Aug-27-18 08:20AM  Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Aug-14-18 07:00AM  CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results PR Newswire
Jul-05-18 07:43AM  Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index Benzinga
Jul-03-18 01:05PM  CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes PR Newswire
Jun-25-18 08:00AM  Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-21-18 04:14PM  Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today Motley Fool
07:00AM  CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol PR Newswire
May-31-18 08:30AM  Free Technical Insights on CASI Pharma and Three Other Biotech Stocks ACCESSWIRE -5.65%
May-29-18 07:00AM  CASI Pharmaceuticals To Present At The BIO International Convention PR Newswire -5.89%
May-15-18 07:00AM  CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results PR Newswire
May-07-18 07:30AM  Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch +11.62%
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
Apr-16-18 07:40AM  Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH ACCESSWIRE
Apr-08-18 07:17AM  What Stocks Perform Well in the Midst of a Trade War? Motley Fool
Apr-06-18 04:23PM  Here's Why CASI Pharmaceuticals Rose as Much as 23.4% Today Motley Fool +13.98%
Apr-05-18 08:00AM  CASI Pharmaceuticals Provides Update On EVOMELA® PR Newswire
Apr-03-18 07:00AM  CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference PR Newswire +47.54%
Mar-29-18 07:00AM  CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results PR Newswire +9.45%
Mar-21-18 08:10AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals ACCESSWIRE
Mar-20-18 09:29AM  CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China PR Newswire +21.81%
Mar-05-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic New Research Emphasizes Economic Growth GlobeNewswire
Feb-09-18 07:00AM  CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference PR Newswire
Jan-30-18 07:50AM  Wired News CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz ACCESSWIRE
Jan-26-18 05:00PM  CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz) PR Newswire
Dec-01-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC) PR Newswire +18.24%
Nov-14-17 07:00AM  CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire +8.37%
Nov-02-17 08:15AM  Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-31-17 07:30AM  CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance ACCESSWIRE
Oct-13-17 10:00AM  CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders PR Newswire -25.27%
Sep-07-17 07:00AM  CASI Provides Pipeline Development Update PR Newswire +5.77%
Sep-06-17 07:00AM  CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference PR Newswire
Aug-14-17 07:00AM  CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
May-30-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC) PR Newswire
May-18-17 07:00AM  CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer PR Newswire
May-15-17 07:00AM  CASI Pharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
Apr-14-17 07:00AM  CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer PR Newswire
Apr-04-17 01:00PM  CASI Exited Fiscal 2016 with a Strong Balance Sheet Zacks Small Cap Research
01:00PM  CASI Exited Fiscal 2016 with a Strong Balance Sheet
Mar-31-17 09:02AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results PR Newswire
Mar-28-17 07:00AM  CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting PR Newswire
Dec-16-16 04:33PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Dec-05-16 11:35AM  CASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
07:00AM  CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA PR Newswire
Nov-19-16 01:04PM  CASI PHARMACEUTICALS, INC. Financials
Nov-14-16 09:04AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an +5.71%
07:00AM  CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results PR Newswire
Oct-25-16 04:31PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Oct-05-16 05:07PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Sep-22-16 05:49AM  Coverage initiated on CASI Pharma by Maxim Group
Aug-16-16 07:00AM  CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma PR Newswire
Aug-15-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:00AM  CASI Pharmaceuticals Reports Second Quarter 2016 Financial Results PR Newswire
Jun-27-16 04:47PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
Jun-13-16 11:18AM  CASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO Zacks Small Cap Research
11:18AM  CASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO
Jun-03-16 04:47PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Jun-01-16 07:00AM  CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) PR Newswire
May-13-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  CASI Pharmaceuticals Reports First Quarter 2016 Financial Results PR Newswire
May-12-16 07:00AM  CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) PR Newswire
Apr-18-16 07:00AM  James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development PR Newswire
Mar-31-16 08:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Mar-30-16 11:51AM  CASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: 2015 By the Numbers
Mar-28-16 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:29AM  CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results at noodls
07:00AM  CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results PR Newswire
Mar-18-16 04:33PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Feb-17-16 04:32PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Feb-10-16 03:17PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Jan-22-16 10:51AM  Charles Schwab Corp (SCHW) and Two Low-Priced Stocks Witness Robust Insider Buying at Insider Monkey
Jan-19-16 08:30AM  CASI Pharmaceuticals Announces Initial Closing Of Its Strategic Financing With Receipt Of $10.3 Million Proceeds PR Newswire
06:05AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Jan-12-16 07:00AM  CASI Pharmaceuticals' Import Drug Registration Application For MARQIBO® Accepted For Review By CFDA PR Newswire
Nov-23-15 02:28PM  Is CASI Pharmaceuticals Inc (CASI) A Good Stock To Buy? at Insider Monkey
Nov-16-15 04:50PM  CASI: Update on Third Quarter Financials
Nov-13-15 09:01AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  CASI Pharmaceuticals Reports Third Quarter 2015 Financial Results PR Newswire
Nov-08-15 05:30PM  Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference PR Newswire
Nov-05-15 09:00PM  Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting PR Newswire
Nov-04-15 07:00AM  CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC) PR Newswire
Oct-23-15 02:01PM  CASI Pharmaceuticals, Inc. Value Analysis (NASDAQ:CASI) : October 23, 2015
Oct-16-15 09:40AM  CASI Receives EU Orphan Drug Designation for ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma
Oct-15-15 08:52AM  Rate Hike Concerns Have Not Affected These Biotechnology Stocks Accesswire
Oct-14-15 12:22PM  CASI Pharmaceuticals (CASI) Stock Spikes on EU Orphan Drug Designation at TheStreet
12:00PM  Why Are These Bio-Tech Stocks Surging Today? at Insider Monkey
07:00AM  CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma PR Newswire
Oct-01-15 04:51PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
10:42AM  CASI Pharmaceuticals, Inc. Earnings Q2, 2015
Sep-22-15 05:01PM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
11:00AM  CASI: New Financing Boosts CASIs Balance Sheet
Sep-21-15 07:00AM  CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants PR Newswire
Aug-24-15 10:30AM  CASI: Update on Second Quarter Financials
Aug-17-15 08:13PM  10-Q for CASI Pharmaceuticals, Inc. at Company Spotlight
Aug-14-15 09:03AM  CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer. The company's late-stage clinical drug candidates, including EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; and ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma. It also offers a portfolio of 25 U.S. food and drug administration-approved abbreviated new drug applications and 1 abbreviated new drug applications. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAPITELLI SARA BVP Fin & Principal Account OffJul 12Option Exercise1.9935,00069,47535,000Jul 13 05:09 PM
CAPITELLI SARA BVP Fin & Principal Account OffApr 12Option Exercise0.8826,97823,74126,978Apr 13 06:03 PM
IDG-Accel China Growth Fund II10% OwnerMar 21Buy3.19204,320651,781646,995Mar 23 03:03 PM
IDG-Accel China Growth Fund II10% OwnerMar 21Buy3.192,882,0989,193,8939,126,375Mar 23 03:03 PM
He Wei-WuDirectorMar 19Buy3.243,086,4199,999,9984,958,024Mar 21 06:53 PM
SPECTRUM PHARMACEUTICALS INC10% OwnerDec 22Buy0.01907,3569,0746,897,413Dec 22 03:38 PM
SPECTRUM PHARMACEUTICALS INC10% OwnerDec 22Buy0.01611,7406,1174,650,262Dec 22 03:38 PM